败血症诊断市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按技术、产品、诊断方法、病原体、地区、竞争细分

2022 年，全球脓毒症诊断市场价值为6.853 亿美元，预计在预测期内将出现令人印象深刻的增长，到2028 年复合年增长率为7.22%。脓毒症是一种危及生命的疾病，当身体对感染的反应变得严重时，就会发生败血症。失调，导致广泛的炎症，并可能导致多重器官功能障碍或衰竭。这是一种严重且进展迅速的疾病，需要立即就医和治疗。败血症通常始于感染，感染可能由细菌、病毒、真菌或寄生虫引起。感染可能有多种来源，例如伤口、泌尿道感染、呼吸道感染或感染的手术部位。当身体检测到感染时，免疫系统会透过释放化学物质来抵抗入侵的病原体。这种免疫反应是遏制和消除感染的自然防御机制。

主要市场驱动因素

市场概况
预测期	2024-2028
2022 年市场规模	57103万美元
2028 年市场规模	87484万美元
2023-2028 年复合年增长率	7.22%
成长最快的细分市场	分子诊断
最大的市场	北美洲

败血症诊断技术的进步

败血症诊断技术的进步对于提高败血症诊断的准确性、速度和效率至关重要。这些创新使医疗保健专业人员能够更早地识别脓毒症并及时启动治疗，这对患者的治疗结果至关重要。聚合酶链反应 (PCR) 技术可以快速检测特定微生物 DNA 或 RNA，从而能够高精度识别引起败血症的病原体。下一代定序（NGS）技术有潜力同时识别多种病原体，并可用于检测导致败血症的已知和新型病原体。自动血液培养系统可自动执行检测血液样本中细菌或真菌生长的过程，比传统的手动方法更快提供结果。带有抗生素中和容器的血液培养瓶有助于克服血液中抗生素的抑製作用，促进败血症患者微生物的恢復。免疫测定可以测量特定细胞因子的水平，例如降钙素原 (PCT) 和 C 反应蛋白 (CRP)，它们被用作评估败血症严重程度的生物标记。侧流分析快速检测可以在护理点检测与败血症相关的生物标记物，从而做出快速诊断和治疗决策。分析宿主免疫反应的基因表现模式可以帮助识别败血症并将其与其他发炎性疾病区分开来。 MicroRNA 光谱已显示出作为脓毒症诊断标记物的前景。

带有生物感测器的 POCT（即时检测）设备可以检测血液样本中与败血症相关的生物标记物，从而在床边快速提供结果。微流控系统能够有效处理小体积样品，并且可以整合到便携式诊断设备中以进行败血症检测。人工智慧和机器学习演算法已应用于败血症诊断。他们可以分析临床资料、实验室结果和生命体征，以识别脓毒症的早期症状，帮助早期介入。超音波、CT 扫描和 MRI 等先进的影像方式可以帮助识别感染迹象，例如脓疡或器官损伤，从而有助于败血症的诊断和监测。多重检测可以同时测量与败血症相关的多种生物标记物，提供更全面的诊断概况。先进的定序技术可以直接对临床样本中的细菌 DNA 进行定序，从而快速识别引起败血症的特定病原体。在 COVID-19 大流行期间，远距医疗平台和远端监控技术变得更加重要，使医疗保健提供者能够远端监控患者并检测败血症的早期迹象。这一因素将有助于全球脓毒症诊断市场的发展。

败血症病例上升

全球败血症的发生率一直在上升。这可以归因于人口老化、慢性病患者数量不断增加以及抗生素抗药性病原体的出现等因素。随着越来越多的人面临败血症的风险，早期准确诊断的需求变得至关重要。大众和医疗保健专业人员对败血症的征兆和症状的认识不断增强。认识的提高导致更多的人在怀疑败血症时寻求医疗救助，从而导致更高的诊断需求。医学科学技术的进步提高了对败血症、其病理生理学以及早期诊断重要性的认识。医疗保健提供者更倾向于使用诊断工具来快速确认或排除败血症。

监管机构和医疗机构越来越重视败血症的早期发现和管理。这导致了指南的製定和采用，建议使用诊断测试来及时识别败血症。由于能够在患者床边快速提供结果，对脓毒症即时检测的需求不断增长。这在急诊和重症监护机构中尤其有价值，因为及时诊断至关重要。败血症治疗的进展，例如新的抗生素和疗法，强调了准确诊断以针对引起感染的特定病原体制定治疗方案的重要性。医疗基础设施和实验室设施的改进使得败血症诊断测试​​的进行变得更加容易，即使在资源有限的环境中也是如此。医疗保健界一直致力于采取感染控制和预防措施，以减少败血症的发生率，但早期发现仍然至关重要。有效的预防和早期诊断相辅相成，可以减少败血症病例。像 COVID-19 大流行这样的事件凸显了诊断在管理包括败血症在内的传染病方面的关键作用。为了应对此类危机，人们对医疗保健基础设施和诊断进行了投资。这项因素将加速全球脓毒症诊断市场的需求。

院内感染的发生率不断增加

院内感染是患者在医疗机构（包括医院和疗养院）逗留期间所获得的感染。如果不及时发现和治疗，这些感染通常会发展为败血症。由于免疫系统减弱、外科手术、侵入性医疗设备（例如导管）和住院时间延长等因素，医疗机构中的患者发生感染的风险较高。如果这些感染没有及时识别和治疗，它们可能会发展为败血症。早期发现 HAI 及其潜在进展为败血症对于患者安全至关重要。败血症诊断在识别有败血症风险的患者方面发挥着至关重要的作用，以便及时介入和治疗。医疗机构实施严格的感染控制措施，以减少医院感染的发生率。这些措施的一部分包括监测和早期发现感染。脓毒症诊断有助于此监测过程，有助于预防脓毒症的发展。在某些情况下，医疗机构可能会爆发特定感染，例如抗甲氧西林金黄色葡萄球菌 (MRSA) 或艰难梭菌 (C. diff) 感染。快速且准确地诊断这些疫情对于遏止传播和预防败血症病例至关重要。

医疗机构须遵守强制监测和报告 HAI 的监管要求和指南。遵守这些法规通常涉及使用败血症诊断来追踪感染率和结果。医院和医疗保健提供者优先考虑患者安全并努力改善临床结果。及时诊断和管理 HAI 引起的脓毒症病例是这些努力的关键组成部分。 HAI 引起的败血症会因住院时间延长、重症监护治疗和额外的医疗干预而显着增加医疗费用。及时诊断和介入有助于减轻医疗保健系统的经济负担。病患权益团体和组织提高了人们对 HAI 风险和感染控制重要性的认识。这导致人们更加关注并强调医疗机构中有效脓毒症诊断的必要性。这项因素将加速全球脓毒症诊断市场的需求。

主要市场挑战

通用竞争

当通用替代品可用于诊断测试时，它们的价格通常比品牌产品更低。这可能会导致市场价格下跌，对生产品牌脓毒症诊断测试​​的公司的收入和利润率带来压力。仿製药製造商可以透过提供具有成本效益的品牌脓毒症诊断测试​​替代品来占领重要的市场份额。这种竞争可能会影响现有诊断公司的市场份额，并可能限制其成长前景。诊断公司通常会在研发上投入大量资源，以创造创新的败血症诊断技术。一旦专利和独占权到期，仿製药製造商就可以合法生产和销售类似的诊断测试，从而降低原始创新者的竞争优势。为了与仿製药竞争，品牌败血症诊断公司可能需要调整其定价策略，这可能会影响其获利能力。降低价格以保持竞争力可能是必要的，但这可能会影响整体市场动态。仿製药竞争的存在可能会阻止公司投资于新的和改进的脓毒症诊断技术的研发。这可能会减慢该领域的创新并限制先进诊断工具的引入。虽然通用诊断测试旨在提供具有成本效益的替代方案，但人们可能会担心这些产品的品质、可靠性和准确性。监管机构在确保通用测试符合必要的品质和安全标准方面发挥着至关重要的作用。

不利影响

脓毒症诊断中使用的一些诊断程序（例如血液培养采集）可能是侵入性的，并且存在不适、感染或其他併发症的风险。虽然这些程序对于准确诊断是必要的，但医疗保健提供者应采取适当的预防措施以尽量减少风险。频繁抽血进行诊断测试可能会导致潜在的不适和併发症，特别是对于重症患者。应有效管理与血液采集相关的风险，例如血肿形成或穿刺部位感染。诊断测试，尤其是在重症监护或紧急情况下，可能会给患者带来焦虑和压力。对于医疗保健提供者来说，有效沟通并为接受败血症诊断的患者提供情感支持至关重要。在某些情况下，可能存在过度使用败血症诊断测试​​的风险，这可能会给患者带来不必要的不​​良和费用。有效的临床指南和决策支援工具对于确保适当的测试利用至关重要。诊断后，脓毒症患者需要持续监测和管理。虽然这本身并不是不良反应，但它是脓毒症护理中预防併发症和优化患者预后的关键方面。

主要市场趋势

生物标记发现

与传统的临床征兆和症状相比，生物标记提供了一种更精确、更具体的方法来识别败血症。这可以实现更早、更准确的诊断，从而及时进行干预。败血症可能会出现与其他疾病重迭的症状。脓毒症特有的生物标记有助于将其与非脓毒症区分开来，从而降低误诊的风险。某些生物标记可以显示败血症的严重程度，帮助医疗保健提供者评估器官功能障碍的程度并相应地调整治疗方案。生物标记可用于监测脓毒症的进展，从而根据需要调整治疗计划。生物标记的发现有助于脓毒症护理中个人化医疗的趋势。根据患者的特定生物标记特征量身订做治疗可以带来更有效和更有针对性的干预措施。脓毒症新型生物标记的鑑定一直是研究和开发工作的重点。这导致新的诊断测试和产品被引入市场。同时测量多种生物标记的多重测定已受到欢迎。这些面板可以提供更全面的诊断资料并提高败血症诊断的准确性。研究表明，使用 microRNA 光谱作为败血症的诊断标记物具有前景。 MicroRNA 生物标记可以提供有关宿主对感染反应的有价值的资讯。

细分市场洞察

技术洞察

2022 年，全球败血症诊断市场将由微生物学技术领域主导，预计未来几年将继续扩大。这可能与以下事实有关：在微生物学技术中使用培养基测试可以精确检测和识别细菌以进行败血症诊断。重要参与者的新策略措施也推动了该领域的扩张。例如，2019年4月，BD推出了全新的BD BACTEC血小板品质控制介质，该介质有助于检测和减少接受血小板输注的患者中的败血症。

产品洞察

2022 年，全球败血症诊断市场将由血液培养基产品领域主导，预计未来几年将持续扩大。在预测期内，该细分市场预计将保持领先地位。这是因为临床医师将血液培养视为最实用、最经济的检测方法。全球市场依类型分为三个产品类别：仪器、血液培养基、检测试剂盒和试剂。在泰国一项针对败血症患者的研究中，发现基于 PCR 的技术 Septifast 检测作为诊断工具比血液培养表现更好。

诊断方法见解

2022 年，全球脓毒症诊断市场将由传统诊断领域主导，预计未来几年将继续扩大。诊断败血症的传统方法取决于医疗保健专业人员的知识来评估患者的临床表现并解读实验室和影像结果。必须快速识别和治疗脓毒症，以改善患者的治疗效果。

病原体洞察

2022年，全球败血症诊断市场最大份额由细菌性败血症领域主导，预计未来几年将持续扩大。由于外科手术的增加、医院传播感染的增加以及细菌性败血症病例的增加。根据SAGE Journals 2019 年1 月发布的报告，细菌性败血症是最常见的形式，62.2% 的患者患有革兰氏阴性菌，46.8% 的患者患有革兰氏阳性菌。市场分为细菌性败血症、真菌性败血症和真菌性败血症。脓毒症和其他基于病原体的脓毒症。在预测期内，预计革兰氏阴性菌细分市场将引领细菌性败血症细分市场。

区域洞察

到 2022 年，北美地区将主导全球败血症诊断市场。在整个预测期内，预计该地区将保持领先地位。这一发展可能与该地区由于拥有强大的医疗基础设施而增加使用先进的诊断工具有关。此外，重要竞争对手的大量存在和有利的报销制度也推动了该领域的市场扩张。此外，预计传染病和败血症盛行率的上升将增加对尖端诊断方法的需求。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球脓毒症诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按技术（分子诊断、微生物学、免疫测定和其他技术）
  • 按产品（仪器、测定和试剂以及其他产品）
  • 依诊断方法（常规诊断和自动诊断）
  • 依病原体（细菌败血症、真菌败血症和其他病原体）
  • 按地区
  • 按公司划分 (2022)
• 市场地图

第 6 章：北美败血症诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按产品分类
  • 按诊断方法
  • 依病原体
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲败血症诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按产品分类
  • 按诊断方法
  • 依病原体
  • 按国家/地区
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区败血症诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按产品分类
  • 按诊断方法
  • 依病原体
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲败血症诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按产品分类
  • 按诊断方法
  • 依病原体
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲败血症诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按产品分类
  • 按诊断方法
  • 依病原体
  • 按国家/地区
• MEA：国家分析
  • 南非败血症诊断
  • 沙乌地阿拉伯败血症诊断
  • 阿联酋脓毒症诊断

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购

第 13 章：全球脓毒症诊断市场：SWOT 分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代治疗类型的威胁

第15章：竞争格局

• 商业概览
• 服务内容
• 最近的发展
• 主要人员
• SWOT分析
  • Abbott Laboratories Inc.
  • DiaSorin SpA
  • Becton, Dickinson and Company
  • BioMerieux Inc.
  • F. Hoffmann-La Roche AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc
  • Siemens Healthineers AG
  • Seegene, Inc.
  • Roche Diagnostics Corporation

第 16 章：策略建议

第 17 章：关于我们与免责声明

Global Sepsis Diagnostics Market has valued at USD 685.30 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.22% through 2028. Sepsis is a life-threatening medical condition that occurs when the body's response to infection becomes dysregulated, leading to widespread inflammation and potentially causing multiple organ dysfunction or failure. It is a severe and rapidly progressing condition that requires immediate medical attention and treatment. Sepsis typically begins with an infection, which can be caused by bacteria, viruses, fungi, or parasites. The infection can originate from various sources, such as a wound, urinary tract infection, respiratory infection, or an infected surgical site. When the body detects an infection, the immune system responds by releasing chemicals to fight off the invading pathogens. This immune response is a natural defense mechanism to contain and eliminate the infection.

In sepsis, the immune response becomes dysregulated or overactive. Instead of effectively targeting the infection, the immune system goes into overdrive, releasing excessive amounts of inflammatory chemicals into the bloodstream. The increasing prevalence of sepsis cases worldwide has been a significant driver for the sepsis diagnostics market. Sepsis is a critical condition that requires early and accurate diagnosis for effective treatment. There has been a growing awareness among healthcare professionals and the general public about sepsis and its potential severity. This awareness has led to increased testing and diagnosis. Continuous advancements in diagnostic technologies, such as molecular diagnostics, immunoassays, and blood culture systems, have improved the accuracy and speed of sepsis diagnosis. These technological innovations have expanded the market by providing more reliable and efficient diagnostic tools. The aging global population is more susceptible to infections and sepsis. As the elderly population continues to grow, the demand for sepsis diagnostics is expected to rise.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 571.03 Million
Market Size 2028	USD 874.84 Million
CAGR 2023-2028	7.22%
Fastest Growing Segment	Molecular Diagnostics
Largest Market	North America

Advancements in Sepsis Diagnostic Technologies

Advancements in sepsis diagnostic technologies have been crucial in improving the accuracy, speed, and efficiency of sepsis diagnosis. These innovations enable healthcare professionals to identify sepsis earlier and initiate timely treatment, which is critical for patient outcomes. Polymerase Chain Reaction (PCR) technology allows for the rapid detection of specific microbial DNA or RNA, enabling the identification of sepsis-causing pathogens with high accuracy. Next-Generation Sequencing (NGS) technology has the potential to identify a wide range of pathogens simultaneously and can be used to detect both known and novel pathogens responsible for sepsis. Automated Blood Culture Systems automate the process of detecting bacterial or fungal growth in blood samples, providing faster results than traditional manual methods. Blood Culture Bottles with Antibiotic Neutralization containers help overcome the inhibitory effects of antibiotics in the bloodstream, enhancing the recovery of microorganisms from septic patients. Immunoassays can measure the levels of specific cytokines, such as procalcitonin (PCT) and C-reactive protein (CRP), which are used as biomarkers to assess the severity of sepsis. Lateral Flow Assays rapid tests can detect sepsis-related biomarkers at the point of care, allowing for quick diagnosis and treatment decisions. Analyzing the gene expression patterns of the host's immune response can help identify sepsis and differentiate it from other inflammatory conditions. MicroRNA profiles have shown promise as diagnostic markers for sepsis.

POCT (Point-of-Care Testing) devices with biosensors can detect sepsis-related biomarkers in blood samples, providing rapid results at the bedside. Microfluidic systems enable the efficient processing of small sample volumes and can be integrated into portable diagnostic devices for sepsis detection. AI and machine learning algorithms have been applied to sepsis diagnostics. They can analyze clinical data, laboratory results, and vital signs to identify early signs of sepsis, aiding in early intervention. Advanced imaging modalities like ultrasound, CT scans, and MRI can help identify signs of infection, such as abscesses or organ damage, aiding in the diagnosis and monitoring of sepsis. Multiplex assays can simultaneously measure multiple biomarkers associated with sepsis, providing a more comprehensive diagnostic profile. Advanced sequencing technologies can directly sequence bacterial DNA in clinical samples, allowing for the rapid identification of specific pathogens causing sepsis. Telemedicine platforms and remote monitoring technologies have become more important during the COVID-19 pandemic, enabling healthcare providers to monitor patients remotely and detect early signs of sepsis. This factor will help in the development of Global Sepsis Diagnostics Market.

Rising cases of Sepsis

The global incidence of sepsis has been on the rise. This can be attributed to factors such as an aging population, a growing number of people with chronic illnesses, and the emergence of antibiotic-resistant pathogens. As more individuals are at risk of sepsis, the need for early and accurate diagnosis becomes crucial. There has been a growing awareness among the public and healthcare professionals about the signs and symptoms of sepsis. Increased awareness leads to more people seeking medical attention when they suspect sepsis, resulting in higher diagnostic demand. Advances in medical science and technology have improved the understanding of sepsis, its pathophysiology, and the importance of early diagnosis. Healthcare providers are more inclined to use diagnostic tools to confirm or rule out sepsis quickly.

Regulatory bodies and healthcare organizations have placed an increased emphasis on the early detection and management of sepsis. This has led to the development and adoption of guidelines that recommend the use of diagnostic tests to identify sepsis promptly. The demand for point-of-care testing for sepsis has grown due to its ability to provide rapid results at the patient's bedside. This is especially valuable in emergency departments and critical care settings, where timely diagnosis is critical. Advances in sepsis treatment, such as new antibiotics and therapies, have underscored the importance of accurate diagnosis to tailor treatment regimens to the specific pathogens causing the infection. Improvements in healthcare infrastructure and laboratory facilities have made it easier to perform sepsis diagnostic tests, even in resource-limited settings. The healthcare community has been working on infection control and prevention measures to reduce the incidence of sepsis, but early detection remains essential. Effective prevention and early diagnosis complement each other in reducing sepsis cases. Events like the COVID-19 pandemic have highlighted the critical role of diagnostics in managing infectious diseases, including sepsis. Investments in healthcare infrastructure and diagnostics have been made in response to such crises. This factor will pace up the demand of Global Sepsis Diagnostics Market.

Increasing Incidence of Hospital-Acquired Infections

Hospital-acquired infections are infections that patients acquire during their stay in a healthcare facility, including hospitals and nursing homes. These infections can often progress to sepsis if not promptly detected and treated. Patients in healthcare settings are at an elevated risk of developing infections due to factors such as weakened immune systems, surgical procedures, invasive medical devices (e.g., catheters), and prolonged hospital stays. If these infections are not promptly identified and treated, they can progress to sepsis. Early detection of HAIs and their potential progression to sepsis is critical for patient safety. Sepsis diagnostics play a crucial role in identifying patients at risk of developing sepsis, allowing for timely intervention and treatment. Healthcare facilities implement rigorous infection control measures to reduce the incidence of HAIs. Part of these measures includes monitoring and early detection of infections. Sepsis diagnostics aid in this monitoring process, helping to prevent the development of sepsis. In some cases, healthcare facilities may experience outbreaks of specific infections, such as methicillin-resistant Staphylococcus aureus (MRSA) or Clostridium difficile (C. diff) infections. Rapid and accurate diagnosis of these outbreaks is essential to contain the spread and prevent sepsis cases.

Healthcare facilities are subject to regulatory requirements and guidelines that mandate the monitoring and reporting of HAIs. Compliance with these regulations often involves using sepsis diagnostics to track infection rates and outcomes. Hospitals and healthcare providers prioritize patient safety and strive to improve clinical outcomes. Timely diagnosis and management of sepsis cases resulting from HAIs are key components of these efforts. Sepsis resulting from HAIs can significantly increase healthcare costs due to prolonged hospital stays, intensive care treatment, and additional medical interventions. Timely diagnosis and intervention can help reduce the economic burden on healthcare systems. Patient advocacy groups and organizations have raised awareness about the risks of HAIs and the importance of infection control. This has led to increased scrutiny and emphasis on the need for effective sepsis diagnostics in healthcare settings. This factor will accelerate the demand of Global Sepsis Diagnostics Market.

Key Market Challenges

Generic Competition

When generic alternatives become available for diagnostic tests, they often come at a lower price than branded products. This can lead to price erosion in the market, putting pressure on the revenues and profit margins of companies manufacturing branded sepsis diagnostic tests. Generic manufacturers can capture a significant share of the market by offering cost-effective alternatives to branded sepsis diagnostic tests. This competition can affect the market share of existing diagnostic companies and potentially limit their growth prospects. Diagnostic companies typically invest substantial resources in research and development to create innovative sepsis diagnostic technologies. Once patents and exclusivity rights expire, generic manufacturers can legally produce and market similar diagnostic tests, reducing the competitive advantage of the original innovator. To compete with generics, branded sepsis diagnostic companies may need to adjust their pricing strategies, which can impact their profitability. Lowering prices to remain competitive may be necessary, but it can affect the overall market dynamics. The presence of generic competition can deter companies from investing in research and development for new and improved sepsis diagnostic technologies. This can slow down innovation in the field and limit the introduction of advanced diagnostic tools. While generic diagnostic tests aim to provide cost-effective alternatives, there may be concerns about the quality, reliability, and accuracy of these products. Regulatory bodies play a crucial role in ensuring that generic tests meet the necessary quality and safety standards.

Adverse Effects

Some diagnostic procedures used in sepsis diagnostics, such as blood culture collection, may be invasive and carry a risk of discomfort, infection, or other complications. While these procedures are necessary for accurate diagnosis, healthcare providers should take appropriate precautions to minimize risks. Frequent blood drawers for diagnostic tests can lead to potential discomfort and complications, especially in critically ill patients. The risks associated with blood collection, such as hematoma formation or infection at the puncture site, should be managed effectively. Diagnostic testing, especially in an intensive care or emergency setting, can cause anxiety and stress for patients. It is essential for healthcare providers to communicate effectively and provide emotional support to patients undergoing sepsis diagnostics. In some cases, there may be a risk of overusing diagnostic tests for sepsis, which can lead to unnecessary discomfort and costs for patients. Effective clinical guidelines and decision support tools are essential to ensure appropriate test utilization. Following diagnosis, patients with sepsis require continuous monitoring and management. While this is not an adverse effect per se, it is a critical aspect of sepsis care to prevent complications and optimize patient outcomes.

Key Market Trends

Biomarker Discovery

Biomarkers provide a more precise and specific way to identify sepsis compared to traditional clinical signs and symptoms. This can lead to earlier and more accurate diagnosis, allowing for timely intervention. Sepsis can present with symptoms that overlap with other medical conditions. Biomarkers that are specific to sepsis help differentiate it from non-septic conditions, reducing the risk of misdiagnosis. Certain biomarkers can indicate the severity of sepsis, helping healthcare providers assess the level of organ dysfunction and tailor treatment accordingly. Biomarkers can be used to monitor the progression of sepsis, allowing for adjustments in treatment plans as needed. Biomarker discovery contributes to the trend of personalized medicine in sepsis care. Tailoring treatment based on a patient's specific biomarker profile can lead to more effective and targeted interventions. The identification of novel biomarkers for sepsis has been a focus of research and development efforts. This has led to the introduction of new diagnostic tests and products onto the market. Multiplex assays that measure multiple biomarkers simultaneously have gained popularity. These panels can provide a more comprehensive diagnostic profile and improve the accuracy of sepsis diagnosis. Research has shown promise in using microRNA profiles as diagnostic markers for sepsis. MicroRNA biomarkers can provide valuable information about the host response to infection.

Segmental Insights

Technology Insights

In 2022, the Global Sepsis Diagnostics Market dominated by microbiology technology segment and is predicted to continue expanding over the coming years. This might be linked to the fact that the use of culture medium tests in microbiology technology enables precise detection and identification of bacteria for sepsis diagnosis. New strategic initiatives by important players are also fuelling the segment's expansion. For instance, in April 2019, BD introduced its brand-new BD BACTEC platelet quality control media, which aids in the detection and reduction of sepsis among patients getting platelet transfusions.

Product Insights

In 2022, the Global Sepsis Diagnostics Market dominated by blood culture media product segment and is predicted to continue expanding over the coming years. Over the forecast period, the segment is anticipated to keep up its lead. This is because clinicians view blood cultures as the most practical and economical testing method. The global market has been divided into three product categories based on type: instruments, blood culture media, and test kits & reagents. In a study on sepsis patients in Thailand, it was found that the Septifast assay, a PCR-based technique, performed better as a diagnostic tool than Blood Culture.

Diagnostic Method Insights

In 2022, the Global Sepsis Diagnostics Market dominated by conventional diagnostics segment and is predicted to continue expanding over the coming years. The traditional approach to diagnosing sepsis depends on the knowledge of healthcare professionals to assess the patient's clinical presentation and decipher lab and imaging results. Sepsis must be quickly identified and treated to enhance patient outcomes.

Pathogen Insights

In 2022, the Global Sepsis Diagnostics Market largest share was dominated by bacterial sepsis segment in the forecast period and is predicted to continue expanding over the coming years. Due to the increase in surgical operations, the growth in hospital-transmitted infections, and the rise in cases of bacterial sepsis. Bacterial sepsis is the most frequent form, with 62.2% of patients having gram-negative bacteria and 46.8% having gram-positive bacteria, according to a report released by SAGE Journals in January 2019. The market is divided into categories for bacterial sepsis, fungal sepsis, and other pathogen-based sepsis. Over the course of the projection period, it is predicted that the gram-negative bacteria sub-segment will lead the market in the bacterial sepsis segment.

Regional Insights

The North America region dominates the Global Sepsis Diagnostics Market in 2022. Throughout the predicted period, it is anticipated that the region would keep up its lead. This development can be linked to the region's increased use of advanced diagnostic tools due to the presence of a strong healthcare infrastructure. Additionally, the market expansion in this area is being fueled by the substantial presence of important competitors and a favorable reimbursement system. Additionally, it is anticipated that the rising prevalence of infectious illnesses and sepsis will increase the need for cutting-edge diagnostic methods.

Key Market Players

• Abbott Laboratories Inc.

• DiaSorin SpA

• Becton, Dickinson, and Company

• BioMerieux Inc.

• F. Hoffmann-La Roche AG

• Danaher Corporation

• Thermo Fisher Scientific Inc

• Siemens Healthineers AG

• Seegene, Inc.

• Roche Diagnostics Corporation

Report Scope:

In this report, the Global Sepsis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sepsis Diagnostics Market, By Technology:

• Molecular Diagnostics
• Microbiology
• Immunoassay
• Other Technologies

Sepsis Diagnostics Market, By Product:

• Instruments
• Assays and Reagents
• Other Products

Sepsis Diagnostics Market, By Diagnostic Method:

• Conventional Diagnostics
• Automated Diagnostics

Sepsis Diagnostics Market, By Pathogen:

• Bacterial Sepsis
• Fungal Sepsis
• Other Pathogens

Global Sepsis Diagnostics Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Sepsis Diagnostics Market.

Available Customizations:

• Global Sepsis Diagnostics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Sepsis Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Molecular Diagnostics, Microbiology, Immunoassay, and Other Technologies)
  • 5.2.2. By Product (Instruments, Assays and Reagents, and Other Products)
  • 5.2.3. By Diagnostic Method (Conventional Diagnostics and Automated Diagnostics)
  • 5.2.4. By Pathogen (Bacterial Sepsis, Fungal Sepsis, and Other Pathogens)
  • 5.2.5. By Region
  • 5.2.6. By Company (2022)
• 5.3. Market Map

6. North America Sepsis Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product
  • 6.2.3. By Diagnostic Method
  • 6.2.4. By Pathogen
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Sepsis Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Diagnostic Method
      • 6.3.1.2.4. By Pathogen
  • 6.3.2. Canada Sepsis Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Diagnostic Method
      • 6.3.2.2.4. By Pathogen
  • 6.3.3. Mexico Sepsis Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Diagnostic Method
      • 6.3.3.2.4. By Pathogen

7. Europe Sepsis Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product
  • 7.2.3. By Diagnostic Method
  • 7.2.4. By Pathogen
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Sepsis Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Diagnostic Method
      • 7.3.1.2.4. By Pathogen
  • 7.3.2. United Kingdom Sepsis Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Diagnostic Method
      • 7.3.2.2.4. By Pathogen
  • 7.3.3. Italy Sepsis Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Diagnostic Method
      • 7.3.3.2.4. By Pathogen
  • 7.3.4. France Sepsis Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Diagnostic Method
      • 7.3.4.2.4. By Pathogen
  • 7.3.5. Spain Sepsis Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Diagnostic Method
      • 7.3.5.2.4. By Pathogen

8. Asia-Pacific Sepsis Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product
  • 8.2.3. By Diagnostic Method
  • 8.2.4. By Pathogen
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Sepsis Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Diagnostic Method
      • 8.3.1.2.4. By Pathogen
  • 8.3.2. India Sepsis Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Diagnostic Method
      • 8.3.2.2.4. By Pathogen
  • 8.3.3. Japan Sepsis Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Diagnostic Method
      • 8.3.3.2.4. By Pathogen
  • 8.3.4. South Korea Sepsis Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Diagnostic Method
      • 8.3.4.2.4. By Pathogen
  • 8.3.5. Australia Sepsis Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Diagnostic Method
      • 8.3.5.2.4. By Pathogen

9. South America Sepsis Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product
  • 9.2.3. By Diagnostic Method
  • 9.2.4. By Pathogen
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Sepsis Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Diagnostic Method
      • 9.3.1.2.4. By Pathogen
  • 9.3.2. Argentina Sepsis Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Diagnostic Method
      • 9.3.2.2.4. By Pathogen
  • 9.3.3. Colombia Sepsis Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Diagnostic Method
      • 9.3.3.2.4. By Pathogen

10. Middle East and Africa Sepsis Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product
  • 10.2.3. By Diagnostic Method
  • 10.2.4. By Pathogen
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Sepsis Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Diagnostic Method
      • 10.3.1.2.4. By Pathogen
  • 10.3.2. Saudi Arabia Sepsis Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Diagnostic Method
      • 10.3.2.2.4. By Pathogen
  • 10.3.3. UAE Sepsis Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Diagnostic Method
      • 10.3.3.2.4. By Pathogen

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Sepsis Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Service Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Abbott Laboratories Inc.
  • 15.5.2. DiaSorin SpA
  • 15.5.3. Becton, Dickinson and Company
  • 15.5.4. BioMerieux Inc.
  • 15.5.5. F. Hoffmann-La Roche AG
  • 15.5.6. Danaher Corporation
  • 15.5.7. Thermo Fisher Scientific Inc
  • 15.5.8. Siemens Healthineers AG
  • 15.5.9. Seegene, Inc.
  • 15.5.10. Roche Diagnostics Corporation

16. Strategic Recommendations

17. About Us & Disclaimer